Quick Answer
GYRE THERAPEUTICS, INC. reported Net Income of $9.88 million for fiscal year 2025.
GYRE THERAPEUTICS, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $9.88M | -44.8% |
| 2024 | $17.90M | +120.9% |
| 2023 | -$85.48M | -2081.5% |
| 2022 | $4.31M | +104.9% |
| 2021 | -$87.93M | -56.4% |
| 2020 | -$56.24M | -1.9% |
| 2019 | -$55.18M | -83.6% |
| 2018 | -$30.05M | -39.4% |
| 2017 | -$21.56M | -27.2% |
| 2016 | -$16.95M | -14.8% |
| 2015 | -$14.76M | -123.2% |
| 2014 | -$6.61M | +33.6% |
| 2013 | -$9.97M | -42.4% |
| 2012 | -$7.00M | +18.0% |
| 2011 | -$8.53M | -178.3% |
| 2010 | $10.90M | +127.7% |
| 2009 | -$39.40M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.94M | +107.8% | +276.6% |
| June 30, 2025 | $1.58M | -65.3% | -57.8% |
| March 31, 2025 | $3.73M | -62.4% | +30.7% |
| September 30, 2024 | $2.86M | -62.0% | -37.1% |
| June 30, 2024 | $4.54M | +20.4% | -54.3% |
| March 31, 2024 | $9.94M | +135.6% | +32.3% |
| September 30, 2023 | $7.51M | +253.8% | +99.2% |
| June 30, 2023 | $3.77M | -92.7% | -10.6% |
- GYRE THERAPEUTICS, INC. showed a decrease of -44.8% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, GYRE THERAPEUTICS, INC.’s net income has grown by 125.1% (from -$39.40 million to $9.88 million).
- The most recent figure is from GYRE THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: